Input parameters for costs
| Cost description . | Cost per 28-day treatment cycle∗, € . | Item number, PPP29 . |
|---|---|---|
| Venetoclax, first line | C1: 65.54 C2: 2457.79 C3-C12: 5243.29 | 532535 |
| Venetoclax, second line | C1: 65.54 C2: 2457.70 C3-C24: 5243.29 | |
| Obinutuzumab | C1: 10 075.16 C2-C6: 3358.39 | 523596 |
| Chlorambucil | C1-C6: 110.86 | 571358 |
| Ibrutinib | 5519.29 | 143617 |
| Rituximab | C1: 1207.08 C2-C6: 1609.44 | 137019 |
| Cost description . | Cost per 28-day treatment cycle∗, € . | Item number, PPP29 . |
|---|---|---|
| Venetoclax, first line | C1: 65.54 C2: 2457.79 C3-C12: 5243.29 | 532535 |
| Venetoclax, second line | C1: 65.54 C2: 2457.70 C3-C24: 5243.29 | |
| Obinutuzumab | C1: 10 075.16 C2-C6: 3358.39 | 523596 |
| Chlorambucil | C1-C6: 110.86 | 571358 |
| Ibrutinib | 5519.29 | 143617 |
| Rituximab | C1: 1207.08 C2-C6: 1609.44 | 137019 |
| Cost description . | Cost, per unit, € . | DRG rate32 . |
|---|---|---|
| CT scan | 324.06 | 30PR06 |
| Out-patient visit | 433.47 | 17MA98 |
| End-of-life, total health care costs | 16 379.00 | 33 |
| Acute coronary syndrome | 1.50 134 | 05MA02 |
| Anemia | 3416.53 | 16MA10 |
| Arthralgia | 433.47 | 17MA98 |
| Asthenia | Not treated | — |
| Atrial fibrillation | 2284.41 | 05MA07 |
| Diarrhea | 908.07 | 06MA11 |
| Dizziness/fatigue | 433.47 | 17MA98 |
| Dyspnea | Not treated | — |
| Febrile neutropenia | 5162.37 | 16MA03 |
| Headache | 433.47 | 17MA98 |
| Hemorrhage | 5721.51 | 17MA01 |
| Hyperglycemia | 893.15 | 23MA03 + long-term admission (€293.68) |
| Hypertension | 2235.22 | 05MA11 |
| Hypogammaglobulinemia | 4989.11 | 16MA07 |
| Infections and infestations | 5376.61 | 18MA08 |
| Infusion-related reaction | 5376.61 | 18MA08 |
| Leukopenia | 433.47 | 17MA98 |
| Myalgia | 433.47 | 17MA98 |
| Neutropenia/neutrophil count decreased | 433.47 | 17MA98 |
| Pneumonia | 5385.75 | 04MA13 |
| Pyrexia | 433.47 | 17MA98 |
| Rash, maculopapular | 274.33 | 09MA98 |
| Sepsis | 6096.91 | 18MA01 |
| Thrombocytopenia | 3651.61 | 16MA09 |
| Tumor lysis syndrome | 835.35 | 10MA01 + long-term admission (€587.37) |
| Urinary tract infection | 5376.61 | 18MA08 |
| Cost description . | Cost, per unit, € . | DRG rate32 . |
|---|---|---|
| CT scan | 324.06 | 30PR06 |
| Out-patient visit | 433.47 | 17MA98 |
| End-of-life, total health care costs | 16 379.00 | 33 |
| Acute coronary syndrome | 1.50 134 | 05MA02 |
| Anemia | 3416.53 | 16MA10 |
| Arthralgia | 433.47 | 17MA98 |
| Asthenia | Not treated | — |
| Atrial fibrillation | 2284.41 | 05MA07 |
| Diarrhea | 908.07 | 06MA11 |
| Dizziness/fatigue | 433.47 | 17MA98 |
| Dyspnea | Not treated | — |
| Febrile neutropenia | 5162.37 | 16MA03 |
| Headache | 433.47 | 17MA98 |
| Hemorrhage | 5721.51 | 17MA01 |
| Hyperglycemia | 893.15 | 23MA03 + long-term admission (€293.68) |
| Hypertension | 2235.22 | 05MA11 |
| Hypogammaglobulinemia | 4989.11 | 16MA07 |
| Infections and infestations | 5376.61 | 18MA08 |
| Infusion-related reaction | 5376.61 | 18MA08 |
| Leukopenia | 433.47 | 17MA98 |
| Myalgia | 433.47 | 17MA98 |
| Neutropenia/neutrophil count decreased | 433.47 | 17MA98 |
| Pneumonia | 5385.75 | 04MA13 |
| Pyrexia | 433.47 | 17MA98 |
| Rash, maculopapular | 274.33 | 09MA98 |
| Sepsis | 6096.91 | 18MA01 |
| Thrombocytopenia | 3651.61 | 16MA09 |
| Tumor lysis syndrome | 835.35 | 10MA01 + long-term admission (€587.37) |
| Urinary tract infection | 5376.61 | 18MA08 |
CT, computed tomography; DRG, Danish diagnosis-related groups; PPP, pharmacy purchase price.
28-day treatment regimens were transformed to fit the model’s 30-day cycle length.